AGC Biologics, Asahi Kasei Enter Clinical Drug Substance Agreement

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Fangzhou Inc. at PHARMCHINA Showcases AI-Powered Healthcare

The 4th Annual "Internet + Pharma" Service Innovation Conference,...

The Evolution of Self-Care: Where Vitauthority Fits in the Wellness Era

Over the past few decades, the concept of self-care...

Piramal Pharma Expands Lexington Sterile Injectables Plant

Piramal Pharma has started work on the expansion of...

China Unveils Innovative Drugs Policy to Boost Development

The National Health Commission and China's National Healthcare Security...

AGC Biologics, a global biopharmaceutical CDMO, entered a new agreement with Asahi Kasei Pharma to produce clinical drug substance for antibody-based therapies at AGC Biologics’ Seattle manufacturing site.

AGC Biologics will leverage its monoclonal antibody development and manufacturing experience to perform process transfer, process optimization, and clinical manufacturing of the Asahi Kasei Pharma drug substance.

During this clinical phase, scientists at the Seattle manufacturing site will work to support process optimization, including product qualification, process development, analytical, and regulatory document support to manufacture the product and prepare it for late phase steps.

AGC Biologics runs multiple mammalian cGMP manufacturing lines at various scales at its Seattle facility. The campus serves as a center of excellence for formulation and employs the latest fed-batch and perfusion manufacturing processes. The site also recently expanded to add a new microbial-based manufacturing line system.

“Our company has a strong history of antibody production, and we pride ourselves on offering the flexibility and the technical expertise to meet any drug substance need at this critical clinical phase,” said JB Agnus, Chief Business Officer, AGC Biologics. “We look forward to partnering with Asahi Kasei Pharma to help achieve their goals with this important project.”

Latest stories

Related stories

Fangzhou Inc. at PHARMCHINA Showcases AI-Powered Healthcare

The 4th Annual "Internet + Pharma" Service Innovation Conference,...

The Evolution of Self-Care: Where Vitauthority Fits in the Wellness Era

Over the past few decades, the concept of self-care...

Piramal Pharma Expands Lexington Sterile Injectables Plant

Piramal Pharma has started work on the expansion of...

China Unveils Innovative Drugs Policy to Boost Development

The National Health Commission and China's National Healthcare Security...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back